Backgrounds Despite the potential therapeutic benefits, cell therapy in renal ischemia-
reperfusion (I/R) injury is currently limited by low rates of cell engraftment after systemic …

Mesenchymal stem cells (MSCs) are a potential therapeutic tool for preventing the
progression of acute kidney injury (AKI) to chronic kidney disease (CKD). Herein, we …

BACKGROUND: Ischemia followed by reperfusion leads to acute renal failure in both native
kidneys and a renal allograft. Our previous study found that transplantation of mesenchymal …

Methods and Results This study was carried out on thirty adult male albino rats. Animals
were divided equally into three groups. Group I (control sham-operated group)(n= 10), were …

Objective (s): Renal ischemia-reperfusion injury (IRI) as a severe condition of acute kidney
injury (AKI) is the most common clinical problem with high mortality rates of 35-60% deaths …

Although previous and ongoing clinical studies have used stromal cells during renal
ischemia-reperfusion injury (IRI), there is little consensus regarding the optimal protocol. We …

Background: Renal ischemia followed by reperfusion leads to acute renal failure in both
native kidneys and renal allograft. This study aimed at investigating the effects …

Introduction Studies have shown that stem cells exert their therapeutic effects on acute
kidney injury (AKI) through paracrine/endocrine actions. If the protective effect is mediated in …

BACKGROUND: Ischemia and reperfusion injury (I/R) is the major cause of acute renal
failure (ARF) with high mortality rates. Because alternative therapies are needed, we …

Acute renal failure (ARF) is a syndrome of abrupt decline in renal function induced by a
number of different insults. In clinic, the common etiology for ARF is ischemia-reperfusion …